A study led by Rare Diseases International finds rare disease patients in Colombia wait an average of 25 months for a diagnosis, and up to 19 years in some cases.
A study led by Rare Diseases International finds rare disease patients in Colombia wait an average of 25 months for a diagnosis, and up to 19 years in some cases.
Colombia’s Consejo de Estado has upheld an order requiring the government to lay the foundations of a new national pharmaceutical policy, with potential consequences for drug pricing, supply, and local …
Mexican pharmaceutical manufacturer Sanfer has invested more than $40 million to expand pharmaceutical production capacity in Colombia, targeting export markets across Latin America and the Caribbean, according to a Sanfer-supported …
Colombia’s highest administrative court suspended Decree 0182 on May 4, 2026, freezing a territorial restructuring of health insurers that would have forcibly reassigned an estimated 6.6 million affiliates.
Colombia’s Ministry of Health declared public interest grounds to pursue mandatory licensing of Gilead’s sofosbuvir-based hepatitis C patents, transferring the process to the competition authority for a final determination.
You must be logged in to post a comment.